Associations - DNA replication inhibitor

BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline SOHO 2023 - 3 weeks (New C4) inotuzumab ozogamicin Sensitive : A2 SOHO 2023 - 3wk	inotuzumab ozogamicin Sensitive: A2 - Guideline SOHO 2023 - 3 weeks inotuzumab ozogamicin Sensitive : A2 SOHO 2023 - 3 weeks - (New C4)
CD33 positive	Acute Myelogenous Leukemia	CD33 positive	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1	gemtuzumab ozogamicin Sensitive: A1 - Approval gemtuzumab ozogamicin Sensitive : A1
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	loncastuximab tesirine Sensitive: A1 - Approval loncastuximab tesirine Sensitive : A1	loncastuximab tesirine Sensitive: A1 - Approval loncastuximab tesirine Sensitive : A1
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1	inotuzumab ozogamicin Sensitive: A1 - Approval inotuzumab ozogamicin Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1
No biomarker	Non-Hodgkin’s Lymphoma	No biomarker	Non-Hodgkin’s Lymphoma	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1	bendamustine Sensitive: A1 - Approval bendamustine Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline carboplatin + etoposide oral + bendamustine Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	CD20 inhibitor + bendamustine Sensitive: A2 - Guideline CD20 inhibitor + bendamustine Sensitive : A2	CD20 inhibitor + bendamustine Sensitive: A2 - Guideline CD20 inhibitor + bendamustine Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2	inotuzumab ozogamicin Sensitive: A2 - Guideline inotuzumab ozogamicin Sensitive : A2
No biomarker	Acute Lymphocytic Leukemia	No biomarker	Acute Lymphocytic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	RUNX1-RUNX1T1 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
CBFB-MYH11 fusion	Acute Myelogenous Leukemia	CBFB-MYH11 fusion	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Acute Promyelocytic Leukemia	No biomarker	Acute Promyelocytic Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2	bendamustine Sensitive: A2 - Guideline bendamustine Sensitive : A2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2	gemtuzumab ozogamicin Sensitive: A2 - Guideline gemtuzumab ozogamicin Sensitive : A2
No biomarker	B Acute Lymphoblastic Leukemia	No biomarker	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2	blinatumomab + inotuzumab ozogamicin Sensitive: A2 - Guideline blinatumomab + inotuzumab ozogamicin Sensitive : A2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	SYD985 Sensitive: B - Late Trials SYD985 Sensitive : B	SYD985 Sensitive: B - Late Trials SYD985 Sensitive : B
DLL3 overexpression	Small Cell Lung Cancer	DLL3 overexpression	Small Cell Lung Cancer	rovalpituzumab tesirine Sensitive: B - Late Trials rovalpituzumab tesirine Sensitive : B	rovalpituzumab tesirine Sensitive: B - Late Trials rovalpituzumab tesirine Sensitive : B
CD123 positive	Acute Myelogenous Leukemia	CD123 positive	Acute Myelogenous Leukemia	IMGN632 Sensitive: C2 – Inclusion Criteria IMGN632 Sensitive : C2	IMGN632 Sensitive: C2 – Inclusion Criteria IMGN632 Sensitive : C2
DLL3 overexpression	Neuroendocrine Tumor	DLL3 overexpression	Neuroendocrine Tumor	rovalpituzumab tesirine Sensitive: C2 – Inclusion Criteria rovalpituzumab tesirine Sensitive : C2	rovalpituzumab tesirine Sensitive: C2 – Inclusion Criteria rovalpituzumab tesirine Sensitive : C2
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2	bosutinib + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria bosutinib + inotuzumab ozogamicin Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	capecitabine + bendamustine Sensitive: C2 – Inclusion Criteria capecitabine + bendamustine Sensitive : C2	capecitabine + bendamustine Sensitive: C2 – Inclusion Criteria capecitabine + bendamustine Sensitive : C2
EGFR overexpression	Glioblastoma	EGFR overexpression	Glioblastoma	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2	ABBV-321 Sensitive: C2 – Inclusion Criteria ABBV-321 Sensitive : C2
CD22 positive	B Acute Lymphoblastic Leukemia	CD22 positive	B Acute Lymphoblastic Leukemia	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2	blinatumomab + inotuzumab ozogamicin Sensitive: C2 – Inclusion Criteria blinatumomab + inotuzumab ozogamicin Sensitive : C2

DNA replication inhibitor

DNA replication inhibitor

Associations(141)

Associations
(141)